A global view of the interplay between non-alcoholic fatty liver disease and diabetes
N Stefan, K Cusi - The lancet Diabetes & endocrinology, 2022 - thelancet.com
Non-alcoholic fatty liver disease (NAFLD) has become an epidemic, much like other non-
communicable diseases (NCDs), such as cancer, obesity, diabetes, and cardiovascular …
communicable diseases (NCDs), such as cancer, obesity, diabetes, and cardiovascular …
[HTML][HTML] Global pandemics interconnected—obesity, impaired metabolic health and COVID-19
Obesity and impaired metabolic health are established risk factors for the non-
communicable diseases (NCDs) type 2 diabetes mellitus, cardiovascular disease …
communicable diseases (NCDs) type 2 diabetes mellitus, cardiovascular disease …
Abnormal liver function tests in patients with COVID‐19: relevance and potential pathogenesis
Lipopolysaccharide Reverses Hepatic Stellate Cell Activation... : Hepatology Lipopolysaccharide
Reverses Hepatic Stellate Cell Activation Through Modulation of cMyb, Small Mothers Against …
Reverses Hepatic Stellate Cell Activation Through Modulation of cMyb, Small Mothers Against …
Extrapulmonary complications of COVID‐19: A multisystem disease?
The outbreak of coronavirus disease 2019 (COVID‐19), caused by the severe acute
respiratory syndrome coronavirus 2 (SARS‐CoV‐2), has been recently declared a pandemic …
respiratory syndrome coronavirus 2 (SARS‐CoV‐2), has been recently declared a pandemic …
Non-alcoholic fatty liver disease
Non-alcoholic fatty liver disease (NAFLD) has a global prevalence of 25% and is a leading
cause of cirrhosis and hepatocellular carcinoma. NAFLD encompasses a disease …
cause of cirrhosis and hepatocellular carcinoma. NAFLD encompasses a disease …
[HTML][HTML] Impact of COVID-19 on the care of patients with liver disease: EASL-ESCMID position paper after 6 months of the pandemic
During the early stages of the coronavirus disease 2019 (COVID-19) pandemic, EASL and
ESCMID published a position paper to provide guidance for physicians involved in the care …
ESCMID published a position paper to provide guidance for physicians involved in the care …
[HTML][HTML] Peer Reviewed: COVID-19 Severity and Mortality Among Chronic Liver Disease Patients: A Systematic Review and Meta-Analysis
R Nagarajan, Y Krishnamoorthy, S Rajaa… - Preventing Chronic …, 2022 - ncbi.nlm.nih.gov
Methods We searched for studies reporting COVID-19 outcomes among CLD and non-CLD
patients in databases including Medline, EMBASE, ScienceDirect, Google Scholar, and …
patients in databases including Medline, EMBASE, ScienceDirect, Google Scholar, and …
The mechanism underlying extrapulmonary complications of the coronavirus disease 2019 and its therapeutic implication
Q Ning, D Wu, X Wang, D Xi, T Chen, G Chen… - Signal transduction and …, 2022 - nature.com
Abstract The coronavirus disease 2019 (COVID-19) is a highly transmissible disease
caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that poses a …
caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that poses a …
COVID‐19 and non‐alcoholic fatty liver disease: two intersecting pandemics
P Portincasa, M Krawczyk, W Smyk… - European journal of …, 2020 - Wiley Online Library
Abstract Background Initial evidence from China suggests that most vulnerable subjects to
COVID‐19 infection suffer from pre‐existing illness, including metabolic abnormalities. The …
COVID‐19 infection suffer from pre‐existing illness, including metabolic abnormalities. The …
Vascular endothelial damage in the pathogenesis of organ injury in severe COVID-19
A Dupont, A Rauch, S Staessens… - … and Vascular Biology, 2021 - Am Heart Assoc
Objective: Whether endotheliopathy only mirrors coronavirus disease 2019 (COVID-19)
severity or plays an intrinsic role in microvascular thrombosis and organ failure remains …
severity or plays an intrinsic role in microvascular thrombosis and organ failure remains …